- Home
- VWAV vs BDTX Comparison
VWAV vs BDTX Comparison
Compare VWAV & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VWAV | BDTX |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VWAV | BDTX |
|---|---|---|
| Price | $10.60 | $2.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 487.3K | ★ 950.8K |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $1.20 |
| 52 Week High | $18.41 | $4.94 |
Technical Indicators
Market Signals| Indicator | VWAV | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 45.08 |
| Support Level | $9.80 | $2.49 |
| Resistance Level | $11.00 | $2.70 |
| Average True Range (ATR) | 1.45 | 0.15 |
| MACD | -0.27 | 0.02 |
| Stochastic Oscillator | 14.67 | 45.19 |
Price Performance
Historical ComparisonAbout VWAV VisionWave Holdings Inc.
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.